Enliven Therapeutics reported a significant increase in liquidity, with cash, cash equivalents, and marketable securities totaling approximately $884.4 million as of September 30, 2026, compared to $462.6 million at year-end 2025. The company is advancing its clinical pipeline, specifically relcobatinib (ELVN-001), and preparing for the ENABLE-2 Phase 3 pivotal trial.
Enliven Therapeutics reported third quarter 2026 financial results and announced alignment with the FDA on the final design of its ENABLE-2 pivotal Phase 3 trial for relcobatinib. The company ended the quarter with $884.4 million in cash and marketable securities, providing a projected cash runway into 2030.
“This quarter marked an important milestone for Enliven as we reached alignment with the FDA on the final design of ENABLE-2, providing a clear path to initiate our first pivotal trial.”
Rick Fair, Chief Executive Officer of Enliven
“As we approach year-end, we remain confident in relcobatinib's potential to become a best-in-class therapy for patients with CML and are focused on executing our Phase 3 development program.”
Enliven Therapeutics CFO Benjamin Hohl Sells $232K of Stock
Benjamin Hohl, CFO, sold 6,018 shares of Enliven Therapeutics, Inc. at $38.48 a share, worth $232K in total on Oct 19, 2026. Shares held after the trade: 38,000 (-13.7%).
Enliven Therapeutics CMO Helen Louise Collins Sells $192K of Stock
Helen Louise Collins, CMO, sold 5,000 shares of Enliven Therapeutics, Inc. at $38.47 a share, worth $192K in total on Oct 19, 2026. Shares held after the trade: 25,000 (-16.7%).